Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application ...

Zealand Pharma A/S (ZEAL) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for Part 1 of ...

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) traded down 2.3% during trading on Wednesday . The stock traded as low as $115.00 and last traded at $115.00. 505 shares traded hands during ...

Zealand Pharma said it has received a complete response letter from the Food and Drug Administration related to its new drug application for dasiglucagon for the prevention and treatment of ...

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III ...

This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK". More infos can be found in our Privacy declaration . If you disagree this ...

Deutsche Bank has initiated coverage on Zealand Pharma (NASDAQ:ZEAL) A/S, traded on both the Copenhagen stock exchange (ZEAL: DC) and NASDAQ (NASDAQ: ZEAL), with a Hold rating and a price target ...

Deutsche Bank (ETR:DBKGn) has initiated coverage on Zealand Pharma (NASDAQ:ZEAL) A/S, traded on both the Copenhagen stock exchange (ZEAL: DC) and NASDAQ (NASDAQ: ZEAL), with a Hold rating and a price ...